AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01828281 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
Study NCT03089450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGBio stent
Description: Percutaneous Coronary Intervention
Study NCT03089450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix flex
Description: Percutaneous Coronary Intervention
Study NCT01476371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group treatment
Description: An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here \& Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
Study NCT02775162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Machine Perfusion (NMP)
Study NCT02775162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (Ice)
Study NCT03287661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavioural Therapy
Description: The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
Study NCT02911441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Study NCT03956628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stay safe program
Description: Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
Study NCT02509156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-MSCs
Description: 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Study NCT02509156 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Study NCT01679860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT
Description: Clin A:~* CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~* HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~* Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation.
Study NCT01679860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clin B (CHOP- CAMPATH) Chemo-immunotherapy
Description: Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course.
Study NCT02547649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114-A
Description: Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
Study NCT04009824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel® Adjuvant
Description: Administered by subcutaneous injection
Study NCT04009824 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Administered by subcutaneous injection
Study NCT04009824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Administered by subcutaneous injection
Study NCT01047462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for acute perforated diverticulitis
Description: Primary resection vs laparoscopic lavage
Study NCT01768702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of C3BS-CQR-1
Description: Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
Study NCT02547649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114-B
Description: Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
Study NCT02547649 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
Study NCT03604146 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medical quality control intervention strategy
Description: Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
Study NCT03347851 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Enrolled patients will complete a non-contrast cardiac MRI
Study NCT01768702 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham, no injection
Description: Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
Study NCT03148899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin Intranasal Spray
Description: In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
Study NCT03148899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Intranasal Spray
Description: The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
Study NCT03347851 — intervention group
Intervention type: OTHER
Intervention: Transthoracic echocardiography exam
Description: Enrolled patients will complete a transthoracic echocardiography exam.
Study NCT04611373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide Levamisole
Description: Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
Study NCT02828462 — intervention group
Intervention type: OTHER
Intervention: CAPRI
Study NCT02114918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Program
Description: Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe.
Study NCT02114918 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition
Description: Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word.
Study NCT03704090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Description: Prevention of postoperative delirium by occupational therapy intervention
Study NCT03704090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-pharmacological prevention intervention
Description: Prevention of postoperative delirium using standard non-pharmacological prevention measures
Study NCT03704090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard non-pharmacological prevention intervention
Description: Prevention of postoperative delirium using standard non-pharmacological prevention measures
Study NCT00218569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone
Study NCT00218569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01588951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine consolidation
Description: Cytarabine-based consolidation per institutional standards.
Study NCT01588951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic transplant
Description: Allogeneic stem cell transplant per institutional standards.
Study NCT00124254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty
Description: Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
Study NCT00124254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Non-surgical usual care
Study NCT00736463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: One arm of randomized crossover
Study NCT00736463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80 mg
Description: Second arm of randomized crossover
Study NCT00467272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
Study NCT04100538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coach
Description: The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes.
Study NCT01640067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Neural Stem Cells
Description: Surgical microinjection of human neural stem cells on spinal cord of ALS patients
Study NCT00404742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID
Study NCT00404742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.2 mg/kg, twice a day (BID)
Study NCT01271049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Food Product
Description: Novel food product containing essential oil blend
Study NCT01271049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Food Product
Description: Control food product
Study NCT00414973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Subcutaneous, 20 micrograms/day, 24 weeks
Study NCT00414973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmon Calcitonin
Description: Intranasal, 200 International Units (IU)/day, 24 weeks
Study NCT02240524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Description: The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
Study NCT02240524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: D2 lymphadenectomy
Description: The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
Study NCT00404742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.4 mg/kg, twice a day (BID)
Study NCT00404742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.6 mg/kg, twice a day (BID)
Study NCT04219215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 100% O2 in oxygen chamber
Description: Application of 100% O2 in an hyperbaric oxygen chamber
Study NCT04219215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 21% O2 in oxygen chamber
Description: Application of ambient air (21% O2) in an hyperbaric oxygen chamber
Study NCT01013584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: daily dose
Study NCT03024034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
Study NCT00843934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
Study NCT00843934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
Study NCT03060317 — intervention group
Intervention type: BEHAVIORAL
Intervention: Examination with neurological scales.
Description: Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
Study NCT01259557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 2 times, Intra-muscular injection, Maximum dosage total 60U
Study NCT02540525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ophira
Description: The procedure will be perfomed with a single incision in anterior wall vagina
Study NCT02540525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator sling
Description: Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
Study NCT04437641 — intervention group
Intervention type: OTHER
Intervention: Tobacco questionnaire
Description: A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact.
Study NCT01974102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
Study NCT01974102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
Study NCT01974102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully for Health (PMH)
Description: Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
Study NCT02240524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Study NCT02143375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 810 Diode Laser
Description: The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
Study NCT02240524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Systemic chemotherapy
Study NCT02240524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Study NCT01832844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group  with scan prior to infiltration 
Description: Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
Study NCT01832844 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group  without scan
Study NCT01128855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg GSK2402968
Description: Weekly subcutaneous injection
Study NCT01128855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg/kg GSK2402968
Description: Weekly subcutaneous injection
Study NCT01128855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9 mg/kg GSK2402968
Description: Weekly subcutaneous injection
Study NCT01128855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mg/kg GSK2402968
Description: Weekly subcutaneous injection
Study NCT01128855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly Placebo
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered via Intravenous (IV) injection